03759 PHARMARON
- 9.840
- -0.150-1.50%
PHARMARON News
Kanglong Chemical (03759) plans to repurchase 200 million to 300 million yuan of A-shares
According to the Zhitong Finance App, Kang Long Huacheng (03759) announced that since the closing price of the company's A shares fell by more than 20% in 20 consecutive trading days as of April 19, 2024, necessary to protect the company's value and shareholders' rights and effectively promote the implementation of the “Double Improvement of Quality and Return” action plan, the company plans to use its own funds to repurchase some of the company's RMB common stock A shares through centralized bidding transactions. The total amount of capital for this repurchase is not less than RMB 200 million and no more than RMB 300 million (all inclusive), and the maximum repurchase price does not exceed
2023年度報告
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
04:14 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Kanglong Chemical (300759): Signed a new rapid growth integrated platform showing resilience
Event: The company achieved operating income of 11.538 billion yuan (+12.4%) and net profit of 1.01 billion yuan (+16.5%) to mother in 2023. 2024Q1 achieved operating revenue of 2,671 billion yuan (-
Express News | Kanglong Chemical: Currently, we have not seen the impact of the Biomedicine Act on customer acquisition
Kanglong Chemical (300759): New orders increased 20% year over year + expected to gradually pick up throughout the year
Incident: Kanglong Chemical released its 2024 quarterly report. In the first quarter of 2024, the company achieved revenue of 2,671 billion yuan (-1.95% YoY), net profit attributable to mother of 231 million yuan (-33.80% YoY), after deducting non-return
Kanglong Chemical (300759): Overseas front-end R&D demand is picking up, and profit margins are expected to improve quarterly
The 2024Q1 results are in line with our expectations for 2024Q1: revenue of 2,671 billion yuan, -2.0% YoY; net profit to mother of 231 million yuan, -33.8% YoY; operating cash flow 7.46
Kanglong Chemical (300759): New orders are improving, and month-on-month improvements can be expected
Guide to this report: New orders are improving, performance is expected to be repaired quarterly, the integrated transformation logic continues to be implemented, optimistic about the company's long-term growth, and maintaining an increase in holdings rating. Investment Essentials: Maintaining an “Overweight” rating. 2024Q1 Revenue 26.71
Kanglong Chemical (300759): Waiting for the inflection point, the order side shows signs of improvement
Matters: The company announced 24Q1 results, achieving revenue of 2,671 billion yuan (yoy -2.0%) and net profit to mother of 231 million yuan (yoy -33.8%). Exclude one-time losses due to the closure of the Shanghai laboratory, and
Kanglong Chemical (300759): New Q1 orders increased by more than 20% year-on-year, demand for downstream innovation gradually picked up
Incident: On April 25, 2024, Kanglong Chemical released its 2024 quarterly report. The company achieved revenue of 2,671 billion yuan in Q1, a year-on-year decrease of 1.95%; net profit to mother was 231 million yuan, a year-on-year decrease of 33 million yuan.
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%
Pharmaron Beijing Co (HKG:3759) reported a profit attributable to owners of 230.6 million yuan for the quarter ended March 31, 2024, down 33.8% from 348.3 million yuan in the previous year, according
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small molecule CDMO are growing rapidly; 2) the clinical research business is progressing steadily, and the macromolecule and CGT sectors are under pressure in the short term; 3) the increase in customer demand sends a positive signal of recovery, keeping the growth guide unchanged throughout the year. (Mainichi Keizai Shimbun)
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
04:40 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy Price (HKD): $9.48, Change: $+0.68, Percent Change: +7.73%
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%
Pharmaron Beijing (HKG:3759) plans to repurchase shares worth 200 million to 300 million yuan from the Shenzhen Stock Exchange through bidding, according to a Thursday filing on the Hong Kong bourse.
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 8% to lead CRO concept stocks, reports say the national level is expected to introduce an action plan for the biological manufacturing industry in the near future
CRO concept stocks increased their gains in the afternoon. As of press release, Tiger Pharmaceuticals (03347) rose 8.39% to HK$33.6; Kanglong Chemical (03759) rose 7.16% to HK$9.43; Pharmaceutical Biotech (02269) rose 6.75% to HK$13.6; and Pharmaceuticals (02359) rose 4.74% to HK$35.35.
Kanglong Chemical (300759): Marginal improvement in order signing is optimistic about the upward trend throughout the year
Internal and external factors have affected the company's performance in the short term, but the amount of new orders has marginally improved the company's 1Q24 to achieve revenue/ adjusted non-IFRS net profit of 2,67/340 million yuan (yoy -2.0%/-22.7
Pharmaron Beijing: Committed to Supporting Partners' Success in Discovery, Development, Commercialization of Innovative Medicines >300759.SZ
Pharmaron Beijing: Committed to Supporting Partners' Success in Discovery, Development, Commercialization of Innovative Medicines >300759.SZ
Pharmaron Beijing: Revenue Temporarily Fell in 1Q Partly Due to Slowdown of Growth in Customer Demand >300759.SZ
Pharmaron Beijing: Revenue Temporarily Fell in 1Q Partly Due to Slowdown of Growth in Customer Demand >300759.SZ
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ
Kanglong Chemical (300759): Performance is under pressure and new orders have ushered in a trend improvement
Event Overview The company announced its 2024 quarterly report: 24Q1 achieved operating income of 2,671 billion yuan, a year-on-year decrease of 1.95%, realized net profit to mother of 231 million yuan, a year-on-year decrease of 33.80%, and realized non-net profit deduction
Analysis
Price Target
No Data
